Tykin Deucravacitinib Cyclosporine
MinorIn clinical trials, taking deucravacitinib together with cyclosporine (a dual Pgp/BCRP inhibitor) caused no clinically significant difference in how the body handles deucravacitinib. The same was seen with fluvoxamine (a CYP1A2 inhibitor), ritonavir (a CYP1A2 inducer), diflunisal (a UGT 1A9 inhibitor), pyrimethamine (an OCT1 inhibitor), famotidine (an H2 receptor antagonist) and rabeprazole (a proton pump inhibitor).
Little or no effect is expected. You usually do not need to change anything, but still tell your doctor or pharmacist about every medicine you take.